

Luf tori

Page 1 of 1



1600

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/447,226A

DATE: 08/19/2002

TIME: 12:53:27

Input Set : A:\6356usp3.txt
Output Set: N:\CRF3\08192002\I447226A.raw

ENTERED

4 <110> APPLICANT: Abbott Laboratories
5 Henkin, Jack
6 Haviv, Fortuna
7 Bradley, Michael F.
8 Kalvin, Douglas M.
9 Schneider, Andrew J.
11 <120> TITLE OF INVENTION: PEPTIDE ANTIANGIOGENIC DRUGS
14 <130> FILE REFERENCE: 6356.US.P3
16 <140> CURRENT APPLICATION NUMBER: 09/447,226A
17 <141> CURRENT FILING DATE: 1999-11-22
19 <150> PRIOR APPLICATION NUMBER: US 09/316,888
20 <151> PRIOR FILING DATE: 1999-05-21
22 <150> PRIOR APPLICATION NUMBER: US 60/126,546
23 <151> PRIOR FILING DATE: 1999-03-26
25 <150> PRIOR APPLICATION NUMBER: US 60/086,536
26 <151> PRIOR FILING DATE: 1998-05-22
28 <160> NUMBER OF SEQ ID NOS: 6
30 <170> SOFTWARE: FastSEQ for Windows Version 4.0
32 <210> SEQ ID NO: 1
33 <211> LENGTH: 10
34 <212> TYPE: PRT
35 <213> ORGANISM: Artificial Sequence
37 <220> FEATURE:
38 <223> OTHER INFORMATION: Antiangiogenic Peptide
40 <221> NAME/KEY: VARIANT
41 <222> LOCATION: (1)...(1)
42 <223> OTHER INFORMATION: Xaa = Ala, Asn, Cit, Gln, Glu, NEtGly, Met,
43 N-methylalanyl, Pro, pyro-Glu, Sar, Ser, or Thr at
44 position 1
46 <221> NAME/KEY: VARIANT
47 <222> LOCATION: (2)...(2)
48 <223> OTHER INFORMATION: Xaa = Ala, Asn, Asp, Gln, Glu, Leu, Met, Phe, Pro,
49 or Ser at position 2
51 <221> NAME/KEY: VARIANT
52 <222> LOCATION: (3)...(3)
53 <223> OTHER INFORMATION: Xaa = Ala, Asn, Cit, Cha, Chg, Gln, Glu, Gly, Ile,
54 Leu, Met, Nva, Phe, Ser, tButylgly, Thr, Val, Pen,
55 or Cys at position 3
57 <221> NAME/KEY: VARIANT
58 <222> LOCATION: (4)...(4)
59 <223> OTHER INFORMATION: Xaa = alloIle, Gly, Ile, Pro, or dehydroleu at
60 position 4
62 <221> NAME/KEY: VARIANT

RECEIVED

AUG 22 2002

TECH CENTER 1600/2900

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/447,226A

DATE: 08/19/2002
TIME: 12:53:27

Input Set : A:\6356usp3.txt
Output Set: N:\CRF3\08192002\I447226A.raw

63 <222> LOCATION: (5)...(5)
64 <223> OTHER INFORMATION: Xaa = Ala, 3-Pal, 1-Nal, 2-Nal, allo-threonyl,
65 allylgly, Gln, Gly, His, Hser, Ile, Lys(Ac), Met,
66 Nva, Octylgly, Orn, Phe(4-CH2OH), Pro, Ser, Thr,
67 Trp, Tyr, Pen, or Cys at position 5
69 <221> NAME/KEY: VARIANT
70 <222> LOCATION: (6)...(6)
71 <223> OTHER INFORMATION: Xaa = Ala, 1-Nal, 2-Pal, Abu, allylgly,
72 Arg, Asn, Asp, Cit, Cha, Gln, Glu, Gly, His,
73 Homoala, Hle, Hser, Ile, Leu, Lys(Ac), Lys(Isp),
74 at position 6
76 <221> NAME/KEY: VARIANT
77 <222> LOCATION: (6)...(6)
78 <223> OTHER INFORMATION: 6 Cont'd:
79 Xaa = Met(O2), Met(O), Met, Nor, Nva, Octylgly,
80 Phe, Phe(4-CONH2), Propargylgly, Ser, Thr, Trp,
81 Tyr, Val, Pen, or Cys at position 6
83 <221> NAME/KEY: VARIANT
84 <222> LOCATION: (7)...(7)
85 <223> OTHER INFORMATION: Xaa = Ala, Allylgly, Asn, Cit, Chg, Gln, Gly,
86 Hser, Ile, alloIle, Leu, Lys(Ac), Met, 1-Nal,
87 2-Nal, Nva, Phe, Pro, Ser, tButylgly, Trp, Tyr,
88 Val, Pen, or Cys at position 7
90 <221> NAME/KEY: VARIANT
91 <222> LOCATION: (8)...(8)
92 <223> OTHER INFORMATION: Xaa = Aminopyrimidinobutanoyl, Ala(3-guanidino),
93 Ala(3-pyrrolidinylamidino), Ala[4-Pip(N-amidino)],
94 Arg, arginyl(NGNG'diethyl), Cit, Cha(4-NIsp),
95 Gly[4-pip(N-amido)], at position 8
97 <221> NAME/KEY: VARIANT
98 <222> LOCATION: (8)...(8)
99 <223> OTHER INFORMATION: 8 Cont'd:
100 Xaa = His, Harg, Lys, Lys(Ile), Lys(Nic), Norarg,
101 Orn(Isp), Orn(Nic), Orn(2-imidazo),
102 Phe(4-CH2NHisp), Phe(4-guanidino), or Phe(4-NIsp)
W--> 103 at position 8
105 <221> NAME/KEY: VARIANT
106 <222> LOCATION: (9)...(9)
107 <223> OTHER INFORMATION: Xaa = Abu, Aib, homoprolyl, hydroxyprolyl, Ile,
108 Leu, Phe, Pro, Ser, tButylgly, Tic, Thr, or Val at
109 position 9
111 <221> NAME/KEY: VARIANT
112 <222> LOCATION: (10)...(10)
113 <223> OTHER INFORMATION: Xaa = azaglycylamide, glycylamide,
114 glycylethylamide, sarcosylamide, serylamide at
115 position 10
117 <400> SEQUENCE: 1 / / /
W--> 118 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
119 1 5 .. 10

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/447,226A

DATE: 08/19/2002
TIME: 12:53:27

Input Set : A:\6356usp3.txt
Output Set: N:\CRF3\08192002\I447226A.raw

122 <210> SEQ ID NO: 2
123 <211> LENGTH: 9
124 <212> TYPE: PRT
125 <213> ORGANISM: Artificial Sequence
127 <220> FEATURE:
128 <223> OTHER INFORMATION: Antiangiogenetic peptide
130 <221> NAME/KEY: VARIANT
131 <222> LOCATION: (1)...(1) /
132 <223> OTHER INFORMATION: Xaa = sarcosyl at position 1
134 <221> NAME/KEY: VARIANT
135 <222> LOCATION: (6)...(6) /
136 <223> OTHER INFORMATION: Xaa = norvaline at position 6
138 <400> SEQUENCE: 2 /
W--> 139 Xaa Gly Val Ile Thr Xaa Ile Arg Pro
140 1 5
143 <210> SEQ ID NO: 3
144 <211> LENGTH: 9
145 <212> TYPE: PRT
146 <213> ORGANISM: Artificial Sequence
148 <220> FEATURE:
149 <223> OTHER INFORMATION: Antiangiogenetic peptide
151 <221> NAME/KEY: VARIANT
152 <222> LOCATION: (1)...(1) /
153 <223> OTHER INFORMATION: Xaa = sarcosyl at position 1
155 <221> NAME/KEY: VARIANT
156 <222> LOCATION: (6)...(6) /
157 <223> OTHER INFORMATION: Xaa = norvaline at position 6
159 <400> SEQUENCE: 3
W--> 160 Xaa Gly Val Gly Thr Xaa Ile Arg Pro
161 1 5
164 <210> SEQ ID NO: 4
165 <211> LENGTH: 9
166 <212> TYPE: PRT
167 <213> ORGANISM: Artificial Sequence
169 <220> FEATURE:
170 <223> OTHER INFORMATION: Antiangiogenetic peptide
172 <221> NAME/KEY: VARIANT
173 <222> LOCATION: (1)...(1)
174 <223> OTHER INFORMATION: Xaa = sarcosyl at position 1
176 <221> NAME/KEY: VARIANT
177 <222> LOCATION: (4)...(4)
178 <223> OTHER INFORMATION: Xaa = allo-isoleucyl at position 4
180 <221> NAME/KEY: VARIANT
181 <222> LOCATION: (6)...(6)
182 <223> OTHER INFORMATION: Xaa = norvaline at position 6
184 <400> SEQUENCE: 4
W--> 185 Xaa Gly Val Xaa Thr Xaa Ile Arg Pro
186 1 5 ^
189 <210> SEQ ID NO: 5

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/447,226A

DATE: 08/19/2002
TIME: 12:53:27

Input Set : A:\6356usp3.txt
Output Set: N:\CRF3\08192002\I447226A.raw

190 <211> LENGTH: 9
191 <212> TYPE: PRT
192 <213> ORGANISM: Artificial Sequence
194 <220> FEATURE:
195 <223> OTHER INFORMATION: Antiangiogenetic peptide
197 <221> NAME/KEY: VARIANT
198 <222> LOCATION: (1)...(1)
199 <223> OTHER INFORMATION: Xaa = sarcosyl at position 1
201 <221> NAME/KEY: VARIANT
202 <222> LOCATION: (4)...(4)
203 <223> OTHER INFORMATION: Xaa = dehydroleucyl at position 4
205 <221> NAME/KEY: VARIANT
206 <222> LOCATION: (6)...(6)
207 <223> OTHER INFORMATION: Xaa = norvaline at position 6
209 <400> SEQUENCE: 5
W--> 210 Xaa Gly Val Xaa Thr Xaa Ile Arg Pro
211 1 5
214 <210> SEQ ID NO: 6
215 <211> LENGTH: 11
216 <212> TYPE: PRT
217 <213> ORGANISM: Artificial Sequence
219 <220> FEATURE:
220 <223> OTHER INFORMATION: Antiangiogenetic Peptide
222 <221> NAME/KEY: VARIANT
223 <222> LOCATION: (1)...(1)
224 <223> OTHER INFORMATION: Xaa = R-(CH₂)_n-C(O)- where R is N-acetylamino at
225 position 1
227 <221> NAME/KEY: VARIANT
228 <222> LOCATION: (2)...(2)
229 <223> OTHER INFORMATION: Xaa = Sar at position 2
231 <221> NAME/KEY: VARIANT
232 <222> LOCATION: (5)...(5)
233 <223> OTHER INFORMATION: Xaa = AlloIle, dehydroleu, Gly, Ile or Pro at
234 position 5
236 <221> NAME/KEY: VARIANT
237 <222> LOCATION: (6)...(6)
238 <223> OTHER INFORMATION: Xaa = Ala, 3-Pal, 1-Nal, 2-Nal, allo-threonyl,
239 allylgly, Gln, Gly, His, Hser, Ile, Lys(Ac), Met,
240 Nva, Octylgly, Orn, Phe(3-CH₂OH), Pro, Ser, Thr,
241 Trp, Tyr, Pen or Cys at position 6
243 <221> NAME/KEY: VARIANT
244 <222> LOCATION: (7)...(7)
245 <223> OTHER INFORMATION: Xaa = Ala, 1-Nal, 2-Nal, 3-Pal, Abu, allylgly,
246 Arg, Asn, Asp, Cit, Cha, Gln, Glu, Gly, His,
247 Homoala, Hle, Hser, Ile, Leu, Lys(Ac), Lys(Isp),
248 at position 7
250 <221> NAME/KEY: VARIANT
251 <222> LOCATION: (7)...(7)
252 <223> OTHER INFORMATION: 7 Con'td:

RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/447,226A

DATE: 08/19/2002
TIME: 12:53:27

Input Set : A:\6356usp3.txt
Output Set: N:\CRF3\08192002\I447226A.raw

253 Xaa = Met(O2), Met(O), Met, Nor, Nva, Octygly,
254 Phe, Phe(4-CONH2), Proparglygly, Ser, Thr, Trp,
255 Tyr, Val, Pen, or Cys at position 7
257 <221> NAME/KEY: VARIANT
258 <222> LOCATION: (11)...(11)
259 <223> OTHER INFORMATION: Xaa = Azaglycylamide, glycylamide,
260 glycylethylamide, sarcosylamide, serylamide at
261 position 11
263 <400> SEQUENCE: 6
W--> 264 Xaa Xaa Gly Val Xaa Xaa Xaa Ile Arg Pro Xaa
265 1 5 10